AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15888797 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha‐2b (1.5 mug/kg) once weekly plus daily ribavirin (1000‐1200 mg) for 48 weeks
Number of subjects: 287
Study 15888797 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha‐2b and ribavirin for 36 weeks
Number of subjects: 287
Study 15888797 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha‐2b and ribavirin for 48 weeks
Number of subjects: 287
Study 11978146 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 60mg with grapefruit juice
Number of subjects: 24
Study 11978146 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5mg with grapefruit juice
Number of subjects: 24
Study 11978146 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine 60mg without grapefruit juice
Number of subjects: 24
Study 11978146 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 5mg without grapefruit juice
Number of subjects: 24
Study 9797051 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) 0.12%
Number of subjects: 15
Study 9797051 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline HCl (TTC) 10 mg/ml
Number of subjects: 15
Study 9797051 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCl (TTC) 50 mg/ml
Number of subjects: 15
Study 9797051 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (control)
Number of subjects: 15
Study 7638969 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) 60 mg once daily
Number of subjects: 36
Study 7638969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1709020 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal aerosol 400 micrograms/day for 21 days and oxymetazoline nasal drops for the first three days
Number of subjects: 130
Study 1709020 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine tablet 60 mg twice/day
Number of subjects: 130
Study 1709020 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms/day with or without oxymetazoline nasal drops
Number of subjects: 130
Study 1709020 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide with oxymetazoline for the first three days
Number of subjects: 130
Study 508019 — intervention group
Group type: EXPERIMENTAL
Intervention: vasodilators
Number of subjects: 10
Study 508019 — intervention group
Group type: EXPERIMENTAL
Intervention: vasodilators plus diuretics
Number of subjects: 10
Study 508019 — intervention group
Group type: EXPERIMENTAL
Intervention: sympatholytics
Number of subjects: 10
Study 508019 — intervention group
Group type: EXPERIMENTAL
Intervention: sympatholytics plus diuretics
Number of subjects: 10
Study 508019 — intervention group
Group type: EXPERIMENTAL
Intervention: sympatholytics, diuretics, and vasodilators
Number of subjects: 10
Study 30318946 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative precautions with mandatory assistive devices and knee brace for 6 weeks
Number of subjects: 394
Study 30318946 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-precaution group with assistive devices only if needed
Number of subjects: 394
Study 30318946 — intervention group
Group type: COMPARATOR
Intervention: Knee brace prescribed in precaution group
Number of subjects: 394
Study 28538371 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 65
Study 28538371 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 65
Study 25609501 — intervention group
Group type: EXPERIMENTAL
Intervention: High value elements (HVEs) of practice redesign
Number of subjects: 0
Study 25609501 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 23684679 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCT group (n=133)
Number of subjects: 266
Study 23684679 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=133)
Number of subjects: 266
Study 20545835 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-adjusting positive airway pressure (APAP)
Number of subjects: 12
Study 20545835 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 12
Study 19994687 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Jiaji (EX‐B 2) combined with blood‐letting and cupping
Number of subjects: 53
Study 19994687 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Valaciclovir Hydrochlordide, Indomethacin, Vitamin B1 and Vitamin B12
Number of subjects: 53
Study 16962390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron preparation 1
Number of subjects: 20
Study 16962390 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron preparation 2
Number of subjects: 20
Study 15295952 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (ASF) mouthrinse
Number of subjects: 12
Study 15295952 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) mouthrinse
Number of subjects: 12
Study 15295952 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial host proteins (LLL) mouthrinse
Number of subjects: 12
Study 11799859 — intervention group
Group type: EXPERIMENTAL
Intervention: Semont maneuver
Number of subjects: 106
Study 11799859 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 106
Study 11799859 — intervention group
Group type: COMPARATOR
Intervention: Brandt & Daroff exercises
Number of subjects: 106
Study 9478093 — intervention group
Group type: COMPARATOR
Intervention: Cholinesterase activity in blood serum of workers
Number of subjects: 0
Study 9478093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase activity in plasma
Number of subjects: 0
Study 9478093 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in cholinesterase activity
Number of subjects: 0
Study 7894213 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine GITS administered at 1000 hours
Number of subjects: 10
Study 7894213 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine GITS administered at 2200 hours
Number of subjects: 10
Study 7894213 — intervention group
Group type: COMPARATOR
Intervention: Placebo period prior to nifedipine administration
Number of subjects: 10
Study 2821953 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants and electroconvulsive therapy
Number of subjects: 51
Study 2821953 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin uptake blockers (alaproclate and zimeldine hydrochloride)
Number of subjects: 51
Study 2821953 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline hydrochloride and electroconvulsive therapy
Number of subjects: 51
Study 2821953 — intervention group
Group type: COMPARATOR
Intervention: Clinically recovered, drug-free patients
Number of subjects: 51
Study 2821953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pretreatment Bmax
Number of subjects: 51
Study 2821953 — intervention group
Group type: EXPERIMENTAL
Intervention: Binding parameters
Number of subjects: 51
Study 31927533 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-gene signature (PEX11A, NLRP2, SERPINE1, UPK, CTTN, D2HGDH)
Number of subjects: 0
Study 29299790 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app (mVIP) with self-care strategies
Number of subjects: 80
Study 26677212 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.0 g/d)
Number of subjects: 193
Study 26677212 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2.0 g/d)
Number of subjects: 193
Study 26677212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 25625366 — intervention group
Group type: EXPERIMENTAL
Intervention: Optisol GS
Number of subjects: 27
Study 25625366 — intervention group
Group type: COMPARATOR
Intervention: Life4°C
Number of subjects: 27
Study 23728101 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE, n=13)
Number of subjects: 26
Study 23728101 — intervention group
Group type: COMPARATOR
Intervention: Resistive exercise (RE, n=13)
Number of subjects: 26
Study 21126528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesions in the medial prefrontal cortex (mPFC)
Number of subjects: 0
Study 21126528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesions in the right mPFC
Number of subjects: 0
Study 21126528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesions in the left posterior cortex (PC)
Number of subjects: 0
Study 21126528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesions in the left hemisphere
Number of subjects: 0
Study 18957452 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care reform support
Number of subjects: 1003
Study 18957452 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering health coverage
Number of subjects: 1003
Study 18957452 — intervention group
Group type: COMPARATOR
Intervention: Plans to terminate coverage or restrict eligibility
Number of subjects: 1003
Study 17203535 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic exclusion and end-to-side colorectal anastomosis (n = 14)
Number of subjects: 32
Study 17203535 — intervention group
Group type: COMPARATOR
Intervention: Subtotal colectomy and end-to-end colorectal anastomosis (n = 18)
Number of subjects: 32
Study 14615296 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based anatomic analysis of the brains with semilobar holoprosencephaly
Number of subjects: 7
Study 14615296 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of the rostro-caudally aligned midline gray matter 'seam'
Number of subjects: 7
Study 14615296 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of telencephalic growth
Number of subjects: 7
Study 12354713 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide with oxygen
Number of subjects: 124
Study 12354713 — intervention group
Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 124
Study 9535210 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP (cisplatin/ifosfamide/etoposide)
Number of subjects: 0
Study 9535210 — intervention group
Group type: COMPARATOR
Intervention: CAV (cyclophosphamide/doxorubicin/vincristine)
Number of subjects: 0
Study 8136590 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous varicocele embolotherapy
Number of subjects: 59
Study 2688231 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg daily for 22 weeks
Number of subjects: 37
Study 2688231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2688231 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg daily for 14 days (after NAC or placebo treatment)
Number of subjects: 37
Study 766252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic BCG (single dose)
Number of subjects: 58
Study 766252 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 30980514 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 2 mg/kg at weeks 0, 4, and every 8 weeks thereafter
Number of subjects: 480
Study 30980514 — intervention group
Group type: COMPARATOR
Intervention: placebo-crossover group
Number of subjects: 480
Study 30980514 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 2 mg/kg
Number of subjects: 480
Study 26788833 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T)
Number of subjects: 627
Study 26788833 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1%/tobramycin 0.3% (DM/T)
Number of subjects: 627
Study 26206652 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Directed Therapy (GDT) using stroke volume variation
Number of subjects: 135
Study 23480249 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 54
Study 23480249 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 54
Study 23480249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 54
Study 22080238 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (group T)
Number of subjects: 0
Study 22080238 — intervention group
Group type: COMPARATOR
Intervention: Propofol (group B)
Number of subjects: 0
Study 19639067 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-implant group
Number of subjects: 86
Study 19639067 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-implant group
Number of subjects: 86
Study 17182196 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer sex behavioral intervention (EDGE)
Number of subjects: 341
Study 17182196 — intervention group
Group type: COMPARATOR
Intervention: Time-equivalent diet-and-exercise attention-control condition
Number of subjects: 341
Study 15489480 — intervention group
Group type: EXPERIMENTAL
Intervention: OBF pneumotonometer
Number of subjects: 127
Study 15489480 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 127
Study 15489480 — intervention group
Group type: COMPARATOR
Intervention: Tono-Pen
Number of subjects: 127
Study 11878524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2.5 mg with fentanyl 0.025 mg
Number of subjects: 40
Study 11878524 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 2.5 mg with fentanyl 0.025 mg
Number of subjects: 40
Study 9187842 — intervention group
Group type: EXPERIMENTAL
Intervention: Petrolatum
Number of subjects: 20
Study 8171069 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 treatment group
Number of subjects: 11
Study 8171069 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 8171069 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 11
Study 3286673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile insulin delivery (5.2 mU kg‐1 min‐1, 2/11 min on/off)
Number of subjects: 16
Study 3286673 — intervention group
Group type: COMPARATOR
Intervention: Continuous insulin delivery (0.8 mU kg‐1 min‐1 for normal men; 0.15 mU kg‐1 min‐1 for type 1 diabetic patients)
Number of subjects: 16
Study 3286673 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 3286673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent insulin delivery (0.97 mU kg‐1 min‐1 for 2 min, followed by 11 min no infusion for type 1 diabetic patients)
Number of subjects: 16
Study 30211787 — intervention group
Group type: EXPERIMENTAL
Intervention: Open semi-extended parapatellar tibial nailing technique (SEK)
Number of subjects: 47
Study 30211787 — intervention group
Group type: COMPARATOR
Intervention: Standard infrapatellar tibial nailing technique (FK)
Number of subjects: 47
Study 28538964 — intervention group
Group type: EXPERIMENTAL
Intervention: mHELP (modified Hospital Elder Life Program)
Number of subjects: 377
Study 28538964 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 377
Study 28538964 — intervention group
Group type: EXPERIMENTAL
Intervention: mHELP
Number of subjects: 377
Study 28538964 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 377
Study 25653317 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative management
Number of subjects: 105
Study 25653317 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 105
Study 23642377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly)
Number of subjects: 0
Study 23642377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (monthly or as-needed)
Number of subjects: 0
Study 23642377 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual Intraretinal Fluid (IRF)
Number of subjects: 0
Study 23642377 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormally thin (<120 μm) or thick (>212 μm) retinas
Number of subjects: 0
Study 23642377 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger neovascular lesions or foveal scar
Number of subjects: 0
Study 21863652 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom SOLO valve
Number of subjects: 69
Study 21863652 — intervention group
Group type: COMPARATOR
Intervention: SJM mechanical valve
Number of subjects: 69
Study 19309712 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI with triple antiplatelet therapy
Number of subjects: 995
Study 19309712 — intervention group
Group type: COMPARATOR
Intervention: Intra-aortic balloon counterpulsation during primary PCI
Number of subjects: 995
Study 19309712 — intervention group
Group type: COMPARATOR
Intervention: Reinfarction
Number of subjects: 995
Study 19309712 — intervention group
Group type: COMPARATOR
Intervention: Stent thrombosis
Number of subjects: 995
Study 16681559 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin inhalation powder (HIIP)
Number of subjects: 16
Study 16681559 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) insulin
Number of subjects: 16
Study 16681559 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SC and HIIP
Number of subjects: 16
Study 15579791 — intervention group
Group type: EXPERIMENTAL
Intervention: 1273AGA allele of the SUR1 gene
Number of subjects: 490
Study 15579791 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk haplotype of the SUR1 gene
Number of subjects: 490
Study 15579791 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk haplotype of the SUR1 gene and 23K allele of the Kir6.2 gene
Number of subjects: 490
Study 11254753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) providing 2.0 g/day of eicosapentaenoate (EPA) and 1.4 g/day of docosahexaenoate (DHA)
Number of subjects: 15
Study 11254753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 15
Study 9430375 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day (group 2)
Number of subjects: 12
Study 9430375 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day (group 1)
Number of subjects: 12
Study 9430375 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 160 mg/day (group 1)
Number of subjects: 12
Study 8214829 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand protocol
Number of subjects: 0
Study 8214829 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 0
Study 3307620 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate lozenges (10 mg), average utilization 5.4 days at an average dose of six lozenges daily
Number of subjects: 55
Study 3307620 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 55
Study 3307620 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate lozenges (10 mg)
Number of subjects: 55
Study 31914165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level intervention exposure
Number of subjects: 0
Study 31914165 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level intervention exposure
Number of subjects: 0
Study 31914165 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29422026 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter with motivational content emphasizing financial benefits
Number of subjects: 4767
Study 29422026 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter with motivational content emphasizing health benefits
Number of subjects: 4767
Study 29422026 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter with motivational content emphasizing values-based benefits
Number of subjects: 4767
Study 29422026 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral letter with no motivational content
Number of subjects: 4767
Study 29422026 — intervention group
Group type: COMPARATOR
Intervention: No letter (reference group)
Number of subjects: 4767
Study 29422026 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with care and coverage from health plan
Number of subjects: 4767
Study 29422026 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with insurance coverage only
Number of subjects: 4767
Study 27632874 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble-board (WB) balance training
Number of subjects: 40
Study 27632874 — intervention group
Group type: COMPARATOR
Intervention: Resistance tubing (RT)
Number of subjects: 40
Study 25075991 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard screw insertion technique (ST group)
Number of subjects: 60
Study 23295793 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene citrate 20 mg
Number of subjects: 1590
Study 23295793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1590
Study 21426748 — intervention group
Group type: COMPARATOR
Intervention: PCI group (50 patients)
Number of subjects: 100
Study 21426748 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy group (50 patients)
Number of subjects: 100
Study 21426748 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy group (50 patients) with MLA < 4.0 mm(2)
Number of subjects: 100
Study 17962712 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea (ECH) 8000 mg/d (5 x 400 mg x 4 times/d for 28 days)
Number of subjects: 24
Study 17962712 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea (ECH)
Number of subjects: 24
Study 17962712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study 14724051 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hydroxy-L-tryptophan (5-HTP) 3-200 mg/kg ip
Number of subjects: 0
Study 14724051 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hydroxy-L-tryptophan (5-HTP)
Number of subjects: 0
Study 14724051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-Hydroxy-L-tryptophan (5-HTP) 1.2-2.0 mg/kg
Number of subjects: 0
Study 14724051 — intervention group
Group type: COMPARATOR
Intervention: 5-Hydroxy-L-tryptophan (5-HTP) with L-valine
Number of subjects: 0
Study 11420028 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate (FP) 400 micrograms/day administered into each nostril twice a day for 45 days
Number of subjects: 43
Study 11420028 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg daily as a single dose for 45 days
Number of subjects: 43
Study 9445199 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotic prophylaxis consisting of novobiocin and rifampin
Number of subjects: 26
Study 9445199 — intervention group
Group type: COMPARATOR
Intervention: Observation alone (Control)
Number of subjects: 26
Study 8037567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow during CPB
Number of subjects: 30